Alzamend Neuro is trading at $1.93, up 11.30%, in pre-market, with no confirmed company-specific catalyst found.
- The company previously announced Phase 1/2A lithium-imaging data would be presented at a Barcelona workshop on September 29. That announcement predates this move and does not confirm new results were released.
- Broad market context is mixed and does not clearly explain the rise; pre-market volume information was unavailable.